Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Clinical research trials and ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC). ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) clinical trial. Participants typically obtain the most effective healthcare available for their ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.

Home > "Z" Clinical Trials Conditions > ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)



ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

For Condition: Carcinoma, Non-Small-Cell Lung
Status: Recruiting
Sponsor(s): AstraZeneca ,
Synopsis: The purpose of the run-in phase of this study is to determine the appropriate and tolerable dose of ZD6474 (200mg or 300mg) to be administered in combination with paclitaxel and carboplatin in subjects with previously untreated locally advanced or metastatic NSCLC. The purpose of the randomization phase of this study is to determine the efficacy of ZD6474 alone versus that of ZD6474 in combination with paclitaxel and carboplatin versus that of paclitaxel and carboplatin alone in subjects with previously untreated locally advanced or metastatic NSCLC.
Details:
Eligibility:
Study Type:
  Interventional, Treatment, Randomized, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Signed informed consent - 18 years or older - Histologically or cytologically confirmed locally advanced or metastatic NSCLC - No prior chemotherapy/biological therapy/radiation therapy - One or more measurable lesions - Life expectancy more than 12 weeks Exclusion Criteria: - Brain metastases or spinal cord compression - Currently active skin disease - History of significant hemoptysis - Abnormal blood chemistry - Cardiac abnormalities - Recent significant cardiac event - Coexisting malignancies
Total Enrollment: 

Location and Contact Information:

Research Site *Recruiting*
Nashville,  Tennessee, 
United States
Recruiting  

Research Site *Recruiting*
Austin,  Texas, 
United States
Recruiting  

Research Site *Recruiting*
St. Louis,  Missouri, 
United States
Recruiting  

Research Site *Recruiting*
Boston,  Massachusetts, 
United States
Recruiting  

Research Site *Recruiting*
Los Angeles,  California, 
United States
Recruiting  

Research Site *Recruiting*
Seattle,  Washington, 
United States
Recruiting  

Research Site *Recruiting*
Chicago,  Illinois, 
United States
Recruiting  

Research Site *Recruiting*
Houston,  Texas, 
United States
Recruiting  


Additional Information:
Study ID Numbers:
  D4200C00007;  D4200C00007(run-in),D4200C0007A (randomization)
Study Start Date: 
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00071188

Other Carcinoma, Non-Small-Cell Lung Studies:
1. Study of Temozolomide in the Treatment of Brain Metastasis from Non-small-cell Lung Cancer

2. ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

3. Study of the Efficacy of an Investigational Drug in Adult Patients with Non Small-Cell Lung Cancer (NSCLC)

4. OSI-774 (Tarceva) in Treating Patients with Stage III or Stage IV Non-Small Cell Lung Cancer

5. Phase 2 Study of TLK286 Administered Weekly in Advanced Non-Small Cell Lung Cancer

Related Studies:

Other Carcinoma, Non-Small-Cell Lung Clinical Trials
Other Washington Clinical Trials
Other Seattle Clinical Trials

ZD6474 Alone or in Combination with Paclitaxel and Carboplatin in Subjects with Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Modify your Search

  Other Carcinoma, Non-Small-Cell Lung Clinical Trials
  Other Washington Clinical Trials
  Other Seattle Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103